ライフサイエンスコーパス: ex-smoker

1 history (24 never-smokers, 16 smokers, and 8 ex-smokers).

2 agnosis were significantly more likely to be ex-smokers.

3 hemoprevention of lung cancer in smokers and ex-smokers.

4 GRQ Total, Symptoms, and Impacts scores than ex-smokers.

5 ation was reduced in smokers but enhanced in ex-smokers.

6 k task (2BT)] in 11 abstinent smokers and 11 ex-smokers.

7 O) levels, independent of whether current or ex-smokers.

8 veral proteins compared to never-smokers and ex-smokers.

9 icity), 841 (13%) smoked and 2136 (33%) were ex-smokers.

10 n to impute missing data and repeated it for ex-smokers.

11 mean age was 67 years; 17 (55%) were smokers/ex-smokers.

12 not differ between non-smokers, smokers, and ex-smokers.

13 in current smokers and 10.5 (5.3-20.0) PY in ex-smokers.

14 n of smoking cessation was 4 (2-8) years for ex-smokers.

15 This immunosuppressive effect may persist in ex-smokers.

16 arker expression in COPD current compared to ex-smokers.

17 al D2R did not differ between nonsmokers and ex-smokers.

18 ion scores compared with both nonsmokers and ex-smokers.

19 a: r = 0.62 and P < .001) but not in healthy ex-smokers.

20 between mGluR5 binding and relapse in recent ex-smokers.

21 ater response was observed in smokers versus ex-smokers.

22 GFR mutation compared with 29% of 14 smokers/ex-smokers.

23 all the never-smokers or all the smokers or ex-smokers.

24 , 20.4% were current smokers, and 19.2% were ex-smokers.

25 ng cessation increases the risk of asthma in ex-smokers.

26 at baseline as occasional, experimental, or ex-smokers.

27 apart were 0.51 for never smokers, 0.48 for ex-smokers, 0.56 for men who smoked < 1 pack/day, and 0.

28 d based on smoking status into smokers (17), ex-smokers (10), and non-smokers (13).

29 er in current smokers (25.9%, P = 0.008) and ex-smokers (28.2%, P = 0.022) than in nonsmokers (38.5%)

30 o be RF positive at baseline (47%) than were ex-smokers (34%) and never smokers (31%).

31 -15.6 coughs/h]), almost double that of COPD ex-smokers (4.9 [2.3-8.7] coughs/h; P = 0.018) and healt

32 active tPA (current smokers, 31+/-23 IU/min; ex-smokers, 50+/-33 IU/min; nonsmokers 202+/-73 IU/min;

33 15 downregulated), and only 8 in smokers vs. ex-smokers (7 upregulated and 1 downregulated).

34 e gray matter mGluR5 DVR between smokers and ex-smokers (9.2%; P < 0.01).

35 iction by investigating a group of long-term ex-smokers (abstinence >1.5 years), and to explore assoc

36 In all ex-smokers, ADC values were significantly elevated in re

37 cancer screening pilot offered to smokers or ex-smokers aged 55-74 years in certain areas of England.

38 AM taken from ex-smokers also failed to secrete significantly increase

39 Ex-smokers also had lower risk-taking to rewards compare

40 urrent smokers, 1.96 (95% CI 1.27 to 3.0) in ex-smokers and 1.27 (95% CI 0.87 to 1.86) in non-smokers

41 odds ratios were 2.5 (95% CI: 1.1, 5.4) for ex-smokers and 1.4 (95% CI: 0.7, 2.9) for current smoker

42 the epsilon3 allele was 1.74 (1.10-2.77) in ex-smokers and 1.68 (1.01-2.83) in smokers, whereas in m

43 Alveolar macrophages of COPD ex-smokers and active smokers had impaired complement-in

44 posure, sex differences were present in both ex-smokers and current smokers for cigarettes per day (P

45 rease in creatinine clearance was greater in ex-smokers and current smokers than in nonsmokers.

46 Long-term ex-smokers and individuals who had never smoked showed n

47 Lung cancer prevention among smokers, ex-smokers and lifetime nonsmokers can be enhanced as we

48 there was no significant difference between ex-smokers and non-smokers in terms of time to Expanded

49 jects with colonized COPD when compared with ex-smokers and nonsmokers.

50 xhibited greater premature responding versus ex-smokers and nonsmokers.

51 In addition, nearly one third of the ex-smokers and smokers classified with the never-smoker-

52 65.6 +/- 6.7 yr; 67.6% male; 23 smokers; 45 ex-smokers) and 24 healthy volunteers (mean age, 57.5 +/

53 ble COPD (COPD), 20 ex-smokers without COPD (ex-smokers), and 15 healthy nonsmokers (nonsmokers).

54 al tobacco smoke exposure, 53 (7.2%) passive ex-smokers, and 121 (16.4%) smokers.

55 odontitis, of which 17 were smokers, 10 were ex-smokers, and 13 were non-smokers.

56 ailability measures of 8 current smokers, 10 ex-smokers, and 18 nonsmokers who were scanned with posi

57 baseline, 49% were current smokers, 21% were ex-smokers, and 30% had never smoked.

58 756 [15.8%] current smokers, 104 604 [1.9%] ex-smokers, and 4 432 871 [82.2%] never smokers) were fo

59 21 (21%) were current smokers, 37 (37%) were ex-smokers, and 43 (43%) had never smoked.

60 61) were current smokers, 28% (328,417) were ex-smokers, and 52% (619,774) were never-smokers.

61 patient cohorts identified as never-smokers, ex-smokers, and current smokers.

62 asked at entry whether they were current or ex-smokers, and how many cigarettes they currently smoke

63 at > or = 100 cfu/ml in 34.6% of COPD, 0% of ex-smokers, and in 6.7% of nonsmokers (p = 0.003).

64 n driving COPD-related inflammation, even in ex-smokers, and might result in activation of the proinf

65 to be married, more likely to be current or ex-smokers, and more likely to be politically liberal th

66 not significantly different between smokers, ex-smokers, and non-smokers.

67 tibility to pulmonary infections in smokers, ex-smokers, and vulnerable populations exposed to second

68 imaries, received IMRT dose >=60 Gy, current/ex-smokers, and/or stage III to IV periodontal condition

69 Those who were ex-smokers at both entry and the 3-year resurvey and had

70 ype 5 (mGluR5) binding in smokers and recent ex-smokers (average abstinence duration of 25 weeks).

71 n exacerbation and improved lung function in ex-smokers but not current smokers with COPD.

72 kers had deeper probing depths than non- and ex-smokers, but pockets were reduced significantly and c

73 number of cigarettes smoked per day and with ex-smokers by the age at which they had quit.

74 ate, putamen, and ventral striatum) and with ex-smokers (caudate and putamen).

75 al significance, as both current smokers and ex-smoker chronic obstructive pulmonary disease (COPD) p

76 Generally, ex-smoker clusters differed from smoking clusters becaus

77 der (b=0.156, 0.057-0.254, p=0.002), and for ex-smokers compared with smokers (b=0.580, 0.467-0.693,

78 nd the decreased down-regulation seen in the ex-smokers could be due to incomplete recovery of the re

79 Smoking status was defined as ex-smoker, current smoker, and never smoker.

80 Smokers, non-smokers, and ex-smokers did not differ significantly in PI, BOP, CAL,

81 ersely, ex-smokers with at least 8 PY (heavy ex-smokers) exhibited a slower decline in CVD risk than

82 time smoking burden of less than 8 PY (light ex-smokers) experienced a significant reduction in CVD r

83 males and females; however, among current or ex-smokers, female first-degree relatives had significan

84 orticosteroids, and had never smoked or were ex-smokers for 1 year or more with 10 pack-years or less

85 For heavy ex-smokers, greater than 25 years might be required for

86 Compared with 14 nonsmokers, 14 ex-smokers had global reductions in the average gray mat

87 However, ex-smokers have a duodenal luminal microbiome that is si

88 ted a dose-dependent association, with light ex-smokers having a CVD risk similar to that of never-sm

89 Being married, living in rural areas, being ex-smokers, having less physical activity and individual

90 Long-term ex-smokers, however, still had higher white blood cell c

91 s (ventilation defects), and gas trapping in ex-smokers in whom FEV1 may be normal and in patients wi

92 cess mortality remains among these long-term ex-smokers, it is only 3% and 10% of the excess mortalit

93 of chronic obstructive pulmonary disease in ex-smokers may be driven, in part, by tobacco anti-idiot

94 These results suggest that with abstinence ex-smokers may recover from low striatal D2R availabilit

95 Results A total of 175 ex-smokers (mean age, 69 years +/- 9 [standard deviation

96 March 2014 to December 2014 and included 58 ex-smokers (mean age, 73 years +/- 9) with (n = 32; mean

97 .1 +/- 12.7 years; 47% men; 28.4% current or ex-smokers; median duration of diabetes 4 [IQR: 1-9] yea

98 tonin metabolism) in current smokers but not ex-smokers might provide clues, but interpretations shou

99 nificantly higher mGluR5 binding than recent ex-smokers, most prominently in the frontal cortex (42%)

100 ges, obtained from nonsmokers (n = 20), COPD ex-smokers (n = 32), and COPD active smokers (n = 64), w

101 enome sequencing data from healthy never and ex-smokers (n = 8), as well as from ex-smokers with vari

102 confidence interval (CI): 1.08 to 1.42]) and ex-smokers (n = 9,381; HR: 1.32 [95% CI: 1.18 to 1.47])

103 y more common in smokers (13%) compared with ex-smokers/never smokers (4%), a relationship which pers

104 er aspirin was seen in the combined group of ex-smokers/never-smoked patients (10.4% vs. 10.6%; HR: 0

105 Patients aged 40 years or older, smokers, or ex-smokers of 10 pack-years or more with spirometrically

106 arettes are increasingly used by smokers and ex-smokers, often to support smoking cessation, but also

107 kers (OR = 0.3, 95% CI: 0.1, 0.7) than among ex-smokers (OR = 0.6, 95% CI: 0.4, 0.9), and there was a

108 current (OR = 1.71, 95% CI = 1.24-2.31) and ex-smokers (OR = 2.83, 95% CI = 2.14-3.72) were consider

109 status was stronger in women (odds ratio for ex-smokers [ORex], 1.44; ORcurrent, 3.45) than in men (O

110 AM from smokers compared with nonsmokers or ex-smokers (P < 0.01).

111 MC among COPD active smokers (P < .0001) and ex-smokers (P = .028).

112 greater in current smokers than in non- and ex-smokers (P<0.005).

113 ial brush cells from 312 stringently defined ex-smoker patients.

114 ed these profiles to those identified in the ex-smoker population to provide a broader understanding

115 ver, in the placebo condition, activation in ex-smokers predominated in the left hemisphere, whereas

116 s overall were driven by current smokers and ex-smokers, probably because of residual confounding by

117 HRs for death in current smokers and ex-smokers relative to never smokers were 2.70 (95% CI 1

118 ited a slower decline in CVD risk than light ex-smokers, requiring more than 25 years for the residua

119 smokers (RR = 0.93; 95% CI = 0.76-1.14) nor ex-smokers (RR = 0.98; 95% CI = 0.75-1.28) were at incre

120 rs (RR, 1.51; 95% CI, 1.04-2.21) and passive ex-smokers (RR, 2.21; 95% CI, 1.39-3.50).

121 sputum from non-smoking (SAn) and current or ex-smoker (SAs/ex) severe asthma patients, mild/moderate

122 one non-smoker (SAn, n = 28) and one current/ex-smoker (SAs/ex, n = 13), and a mild-moderate asthma g

123 Long-term ex-smokers showed significantly higher mGluR5 binding th

124 ritish ethnicity (0.67, 0.53-0.84, p=0.001); ex-smoker status (1.29, 1.05-1.57, p=0.014); TC higher t

125 higher than 7.5 mmol/L, statin prescription, ex-smoker status, high-frequency GP attendance, and regi

126 nd chronic bronchitis, limited to current or ex-smokers, suggests genetic risk factor(s) for COPD tha

127 al processes, were fourfold more frequent in ex-smokers than current smokers and had considerably lon

128 h stronger association in current and recent ex-smokers than in long-term ex- and never-smokers; the

129 ents were significantly different in healthy ex-smokers than they were in ex-smokers with COPD.

130 or moderate dysplasia were more likely to be ex-smokers than those with grades of regular metaplasia

131 h the benefits, yet for most nonsmokers (and ex-smokers), the benefits of radiotherapy far outweigh t

132 choscopic sampling of NBECs from smokers and ex-smokers then will allow susceptible individuals to be

133 After excluding current and ex-smokers there were 226 cases and 450 disease-free con

134 However, in ex-smokers, these proteins return to similar levels to t

135 re underexpressed when comparing smokers and ex-smokers to non-smokers.

136 ceptor binding were acquired in 14 long-term ex-smokers, using positron emission tomography with radi

137 In all ex-smokers, VDP was correlated with PRM gas trapping (r

138 (16 upregulated and 7 downregulated), 17 in ex-smokers vs. non-smokers (2 upregulated and 15 downreg

139 r-smokers, risk of coronary heart disease in ex-smokers was 1.34 (95% CI 0.86-2.08) and in smokers it

140 ery of the receptors, especially because the ex-smokers were abstinent for only 25 wk on average.

141 Among e-cigarette/HTP users, ex-smokers were more likely than current smokers to use

142 Ex-smokers who had stopped by choice (only 3% of ever-sm

143 Among ex-smokers who had stopped permanently at ages 25-34 yea

144 biome in never-smokers, current smokers, and ex-smokers who quit >= 10 years ago.

145 Ex-smokers who stopped smoking either before or after th

146 topped because of illness, but not the other ex-smokers, who are described as having stopped by choic

147 Compared with current smokers, ex-smokers with a lifetime smoking burden of less than 8

148 We analyzed the nuclear lung proteomes of ex-smokers with and without the disease.

149 Ex-smokers with asthma appeared to have evidence of an o

150 Ex-smokers with asthma had a significant improvement in

151 placebo for 2 weeks in smokers with asthma, ex-smokers with asthma, and never-smokers with asthma.

152 never smokers and CCL5 and CXCL10 reduced in ex-smokers with asthma.

153 prednisolone) in 22 current, 21 never and 10 ex-smokers with asthma.

154 Conversely, ex-smokers with at least 8 PY (heavy ex-smokers) exhibit

155 Twenty-two ex-smokers with combined chronic obstructive pulmonary d

156 as also significantly correlated with PRM in ex-smokers with COPD (gas trapping: r = 0.47 and P = .03

157 ers with (n = 14) and without COPD (n = 17), ex-smokers with COPD (n = 13), and nonsmokers (n = 12).

158 lood and alveolar macrophages--obtained from ex-smokers with COPD (n = 14), ex-smokers without COPD (

159 th neutrophilic airway lumen inflammation in ex-smokers with COPD and could contribute to progression

160 Conversely, ex-smokers with COPD showed an increase in ac-H3 (p < 0.

161 rent in healthy ex-smokers than they were in ex-smokers with COPD.

162 tes as chemopreventive agents in smokers and ex-smokers with early lung lesions.

163 moking history of at least 30 pack-years and ex-smokers with less than 15 years since quitting.

164 Never smokers and ex-smokers with MS had similar mortality rates compared

165 al study of 262 lung samples derived from 34 ex-smokers with normal lung function (n = 10) or GOLD st

166 , both of which were unexpectedly present in ex-smokers with normal spirometry and CT findings.

167 rametric response map (mPRM) measurements in ex-smokers with or without COPD by using volume-matched

168 risks that compared categories of smokers or ex-smokers with otherwise similar never-smokers.

169 ed from nonsmoking patients with SA, smokers/ex-smokers with severe asthma, nonsmoking patients with

170 We studied 23 current or ex-smokers with similar smoking histories with COPD (n =

171 as performed in three groups of subjects: 26 ex-smokers with stable COPD (COPD), 20 ex-smokers withou

172 ever and ex-smokers (n = 8), as well as from ex-smokers with variable degrees of COPD (n = 4).

173 s: 26 ex-smokers with stable COPD (COPD), 20 ex-smokers without COPD (ex-smokers), and 15 healthy non

174 obtained from ex-smokers with COPD (n = 14), ex-smokers without COPD (n = 15), and nonsmokers (n = 9)

175 Ex-smokers without COPD had a larger fraction of normal

176 ly; P < .001), both of which were present in ex-smokers without COPD.

177 , 92 (12.5%) passive nonsmokers, 157 (21.3%) ex-smokers without environmental tobacco smoke exposure,

178 tality rates compared with never smokers and ex-smokers without MS in the male British doctors cohort

179 nd matched to never-smokers (NS, n = 27) and ex-smokers (XS, n = 27) by age (+/- 5 years), body mass